Diaceutics (GB:DXRX) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Diaceutics PLC has expanded its precision medicine services for rare diseases, including the addition of new genomic lab data partners and the enhancement of its data processing capabilities. This expansion has enabled Diaceutics to secure a new contract aimed at supporting the commercialization of a therapy for a rare genetic disorder, demonstrating the company’s commitment to improving early diagnosis and treatment for patients with rare diseases.
For further insights into GB:DXRX stock, check out TipRanks’ Stock Analysis page.